Enzymotec to Report First Quarter 2016 Financial Results
May 05, 2016 08:30 ET
|
Enzymotec Ltd.
MIGDAL HA'EMEQ, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...
Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT® Uses Promoting Development of Beneficial Gut Flora and Reducing Infant Crying Duration
March 29, 2016 08:30 ET
|
Enzymotec Ltd.
MIGDAL HA'EMEQ, Israel, March 29, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...
InCog™, Enzymotec's Innovative Lipid Composition for Cognitive Functioning, Enhances Brain Development and Improves Survival in Preclinical Study
March 16, 2016 08:30 ET
|
Enzymotec Ltd.
MIGDAL HA'EMEQ, Israel, March 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (NASDAQ:ENZY) (“Company” or "Enzymotec"), a developer, manufacturer and marketer of innovative bio-active lipid based...
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2015
March 08, 2016 16:30 ET
|
Enzymotec Ltd.
MIGDAL HA’EMEQ, Israel, March 08, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (“Company”), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional...
CORRECTING and REPLACING -- Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results
February 17, 2016 09:07 ET
|
Enzymotec Ltd.
Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter...
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results
February 17, 2016 07:30 ET
|
Enzymotec Ltd.
Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter...
Enzymotec to Report Fourth Quarter and Full Year 2015 Financial Results
February 03, 2016 08:30 ET
|
Enzymotec Ltd.
MIGDAL HA'EMEQ, Israel, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods,...
Enzymotec Announces Positive Outcome in ICC Arbitration Award
February 02, 2016 08:30 ET
|
Enzymotec Ltd.
Arbitration tribunal rejects AAK’s requests for declaratory relief in their entirety Finds in accordance with Enzymotec’s position that the joint venture agreement may be terminated only through...
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31, 2019
January 04, 2016 08:00 ET
|
Enzymotec Ltd.
MIGDAL HA’EMEQ, Israel, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional...
Enzymotec Granted Mexican Patent for INFAT® Uses Related to Promoting Intestinal Health
December 21, 2015 08:30 ET
|
Enzymotec Ltd.
MIGDAL HA'EMEQ, Israel, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...